10-K: Biomerica Reports FY25 Loss Amid Product Launches, Cost Cuts

Biomerica, a biomedical technology company, reported a net loss of $4.97 million for fiscal year 2025, alongside a 2% decrease in net sales, while actively pursuing commercialization of its inFoods IBS and hp+detect products and implementing significant cost-cutting measures.

Summary

• Net sales decreased by 2% to $5.31 million in fiscal year 2025, compared to $5.42 million in fiscal year 2024.
• The company reported a net loss of $4.97 million for fiscal year 2025, an improvement from a $5.98 million net loss in fiscal year 2024.
• Operating loss for fiscal year 2025 was $5.14 million, down from $6.37 million in fiscal year 2024.
• Research and development expenses decreased by 31% to $1.02 million in fiscal year 2025, reflecting a transition to commercialization and cost management efforts.
• Selling, General and Administrative (SG&A) expenses decreased by 16% to $4.61 million in fiscal year 2025, primarily due to a workforce reduction and lower stock compensation.
• Cash and cash equivalents decreased to $2.40 million as of May 31, 2025, from $4.17 million as of May 31, 2024.
• Working capital decreased to $3.14 million as of May 31, 2025, from $5.53 million as of May 31, 2024.
• The company raised $2.015 million in net proceeds from an At-The-Market (ATM) offering during fiscal year 2025.
• A 1-for-8 reverse stock split became effective on April 21, 2025.
• The independent registered public accounting firm issued a report expressing substantial doubt about the company's ability to continue as a going concern.
• Subsequent to year-end, in July 2025, the company received a $1.1 million cash refund from the IRS related to Employee Retention Credit (ERC).
• Additional sales of common stock under the ATM offering in July and August 2025 generated approximately $919,000 in net proceeds.

Sentiment

Score: 3

Explanation: While cost-cutting measures and recent capital raises provide some temporary relief, the persistent operating losses, negative cash flows, and the explicit 'going concern' warning from the independent auditor indicate significant financial distress and uncertainty. The slower-than-expected launch of key products further dampens the outlook, suggesting a high-risk investment profile despite strategic efforts.

Positives

• Net loss decreased to $4.97 million in FY2025 from $5.98 million in FY2024, indicating an improvement in bottom-line performance.
• Operating loss decreased significantly to $5.14 million in FY2025 from $6.37 million in FY2024, driven by effective cost management.
• Research and development expenses were reduced by 31% ($468,000) in FY2025, reflecting a strategic shift towards commercialization and cost preservation.
• Selling, General and Administrative expenses decreased by 16% ($875,000) in FY2025, primarily due to a 15% workforce reduction and lower stock compensation, demonstrating disciplined capital management.
• The inFoods IBS product has been launched to gastroenterology physician groups, with generally positive initial feedback and ongoing expansion efforts.
• FDA 510(k) clearance was received for hp+detect, a diagnostic test for Helicobacter pylori, positioning it for commercial adoption.
• Contract manufacturing billings increased by 44% to $1.07 million in FY2025, offsetting some declines in other segments.
• The backlog of unshipped orders increased to $1.32 million as of May 31, 2025, from $755,000 in FY2024, indicating future revenue potential.
• Successfully raised $2.015 million in net proceeds from an ATM offering in FY2025, providing additional liquidity.
• Received a $1.1 million cash refund from the IRS for the Employee Retention Credit in July 2025, further bolstering liquidity.
• A strong patent portfolio protects the inFoods technology platform, with 15 patents granted globally for IBS and other inflammatory diseases, providing competitive advantages.
• The last FDA inspection in May 2024 resulted in no observations, indicating compliance with regulatory standards.

Negatives

• Net sales decreased by 2% to $5.31 million in FY2025, primarily due to reduced retail market activity, lower international over-the-counter sales, and volatility in clinical laboratory demand.
• The company has a history of operating losses and negative cash flows from operations, with an accumulated deficit of $53.17 million as of May 31, 2025.
• Current cash and cash equivalents are insufficient to meet operating plans for the next 12 months, leading to substantial doubt about the company's ability to continue as a going concern.
• Gross profit decreased from $611,000 in FY2024 to $498,000 in FY2025, and cost of sales as a percentage of net sales increased from 89% to 91%.
• Dividend and interest income decreased by $266,000 in FY2025 due to lower market interest rates and reduced cash balances.
• Key product launches, inFoods IBS and hp+detect, have been slower than expected, necessitating significant cost-cutting measures.
• The company relies on a limited number of key distributors; one distributor accounted for 31% of net sales in FY2025, and four distributors accounted for 69% of gross accounts receivable as of May 31, 2025.
• The workforce reduction of approximately 15% incurred severance costs and may create concerns about job security, potentially leading to the loss of key employees.
• Exposure to international risks, including economic fluctuations, regulatory changes, geopolitical instability, tariffs, and currency exchange fluctuations, could negatively impact foreign sales and collection of receivables.
• Reliance on a limited number of suppliers for certain critical raw materials, such as antibodies, poses a risk of supply challenges or increased costs.
• The company faces intense competition from larger, better-resourced medical and pharmaceutical companies.
• Evolving EU IVDR requirements may increase compliance costs and extend certification timelines, potentially limiting the ability to sell certain IVDD products in the EU.
• The company's public float is less than $75 million, which limits the aggregate market value of securities that can be sold under its Form S-3 shelf registration statement to one-third of its public float ($3.32 million over any 12 consecutive months).

Risks

• The ability to raise additional capital and continue as a going concern is uncertain.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing may be inaccurate.
• The ability to establish and maintain intellectual property rights covering products and technology is crucial for competitive advantage.
• Intense competition from companies with significantly greater financial, technical, and marketing resources poses a threat to market share.
• The company must obtain and maintain government or regulatory certification in various countries, including meeting new EU IVDR testing and documentation requirements, which could increase costs and extend timelines.
• Maintaining relations with key distributors is critical, as the loss of any key distributor could lead to reduced sales.
• Global economic and political developments, including rising inflation, interest rates, capital market disruptions, and trade disputes, could harm business operations.
• The implementation of the business model and strategic plans for products and technology carries inherent risks.
• Third parties may assert intellectual property infringement claims, leading to significant costs or product redesigns.
• Compliance with numerous laws and regulations, as they currently exist or are modified, could increase costs and affect operations.
• Risks related to product recalls, claims of liability, or harm to patients/users could adversely affect the business and reputation.
• The ability to retain key personnel and to identify, hire, and retain additional qualified professionals is essential for future success.
• Operating results are subject to fluctuations due to factors outside control, such as regulatory clearances, reimbursement changes, and market penetration of new products.
• A significant portion of operating expenses are fixed, making it difficult to adjust rapidly if revenues fall short of expectations.
• There is no assurance that efforts to develop new technologies, products, or markets will be successful or commercially viable.
• Operating a manufacturing plant in Mexico introduces risks related to local economic and political conditions, social unrest, export/import restrictions, currency fluctuations, and labor shortages.
• The use of hazardous materials in research and production presents risks of accidental contamination, injury, and significant liability.
• Reliance on a limited number of key distributors for a substantial majority of total revenue creates vulnerability.
• International sales face distinct risks, including compliance challenges, tariffs, currency exchange fluctuations, payment difficulties, and reduced intellectual property protection.
• The financial soundness of customers, distributors, and suppliers could adversely affect operational results and financial condition.
• Collecting receivables, particularly from international customers, can be challenging due to difficulties in obtaining reliable credit information and enforcing collections through foreign legal systems.
• Failure to effectively manage growth, including scaling operational systems and entering new markets, could adversely affect operating results.
• Intellectual property risks include the potential for theft, inability to attain adequate patent claims, and third-party claims of infringement or misappropriation.
• Failures in information technology and storage systems or data security breaches could disrupt business and incur excessive costs.
• The recent workforce reduction places increased workload on remaining employees and may lead to the loss of key talent.
• Future sales of common stock in the public market could lower the market price and dilute existing stockholders' interests.
• The price of the company's stock may fluctuate unpredictably in response to factors unrelated to operating performance.
• The ability to use net operating loss carryforwards in the future may be subject to limitation under IRC Sections 382 and 383.
• Clinical trials are lengthy, expensive, and have uncertain outcomes, and results may not be predictive of future trial results.
• Reliance on third parties to conduct clinical trials introduces risks of non-compliance, delays, or unreliable data.

Future Outlook

The company aims to increase revenue from international opportunities and new product launches, particularly inFoods IBS and hp+detect. It is actively pursuing US government payer reimbursement for inFoods IBS, which is anticipated to significantly boost revenues if successful, followed by applications for private payer insurance reimbursement. Management is exploring distribution, partnership, and licensing opportunities for its key products to support broader market launches. To address capital needs and sustain operations, the company is pursuing strategies to increase sales, reduce expenses, sell non-core assets, and seek additional debt or equity financing. The company believes its current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months.

Management Comments

• "The decrease [in R&D expenses] reflects our transition from intensive product development to the commercialization phase of inFoods IBS and hp+detect, as well as our broader efforts to manage costs and preserve cash."
• "GI physician feedback has been generally positive, and we are continuing to expand our presence in the GI segment while exploring opportunities to bring the inFoods technology to other medical specialties."
• "We are actively pursuing insurance reimbursement for the InFoods IBS product in conjunction with our CLIA laboratory partner."
• "We are actively promoting hp+detect to large end-customer laboratories and positioning the product for commercial adoption."
• "Due to the slower-than-expected launch of our key products, inFoods IBS and hp+detect, we have initiated significant cost-cutting measures to extend our cash runway and work towards increasing revenues to cover overhead costs."
• "Management has analyzed the Company’s cash flow requirements through August 2026 and beyond. Based on this analysis, we believe our current cash and cash equivalents are insufficient to meet our operating cash requirements and strategic growth objectives for the next twelve months."
• "To address our capital needs and sustain operations beyond the next year, we are actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and seek other strategic alternatives."

Industry Context

The medical diagnostics industry is highly competitive, characterized by numerous multinational and regional players, many of whom possess significantly greater financial and technical resources than Biomerica. There is a noticeable trend towards industry consolidation. Technological advancements are driving the shift towards rapid, point-of-care, and home-use diagnostic tests, which aligns with Biomerica's product development strategy. The industry is heavily regulated by agencies like the FDA and European bodies (e.g., CE Mark, IVDR), with evolving and more stringent requirements increasing compliance costs and potentially extending certification timelines. Reimbursement policies from third-party payers significantly influence product adoption and profitability, creating pressure to reduce healthcare costs.

Management Changes

Corporate Governance

Legal Proceedings

• As of May 31, 2025, there were no pending legal proceedings. Management believes any future legal matters will not have a material adverse effect on the company's consolidated financial position, results of operations, or cash flows.

Related Party Transactions

• The company holds an investment of approximately $165,000, representing 6% ownership, in a privately held Polish distributor that distributes the company's products.
• A royalty agreement exists where the company obtained rights to manufacture and market an Adrenocorticotropic Hormone (ACTH) test, incurring royalty expenses of approximately $7,000 in FY2025 and $10,000 in FY2024, included in cost of sales. Sales under this agreement are not material to total sales.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity offerings to raise capital, and potential for stock price decline due to the going concern warning and persistent operating losses. The reverse stock split aimed to increase share price but does not resolve underlying financial issues.
• Employees experienced a workforce reduction of approximately 15% during FY2025, which incurred severance costs and may lead to increased workload for remaining staff and concerns about job security, potentially impacting talent retention.
• Customers could be affected by potential product recalls or claims of defects, which could harm the company's reputation and product availability. Inability to meet unexpected increases in demand could also negatively impact customer relationships.
• Suppliers face risks related to the company's financial soundness, as difficulties in payment or credit restrictions could arise if the company's financial performance deteriorates.
• Creditors are exposed to higher risk due to the company's recurring operating losses, negative cash flows, and the explicit 'going concern' doubt, indicating potential challenges in meeting future obligations.

Next Steps

• Expand presence in the gastroenterology segment and explore opportunities to introduce inFoods technology to other medical specialties.
• Evaluate distribution, partnership, and licensing opportunities with large U.S. companies for broader market launch of inFoods products.
• Actively pursue US government payer reimbursement for the inFoods IBS product through the Medicare system, and subsequently apply for private payer insurance reimbursement.
• Actively promote hp+detect to large end-customer laboratories to position it for commercial adoption.
• Implement strategies to increase sales, reduce expenses, sell non-core assets, and seek additional financing through debt or equity to meet capital requirements and sustain operations.
• Update technical documentation and processes to comply with the more stringent EU IVDR requirements.
• Monitor and evaluate the effectiveness of disclosure controls and procedures and internal controls over financial reporting on an ongoing basis.

Key Dates

Recommendation

The company faces significant financial challenges, including recurring operating losses, negative cash flows, and an accumulated deficit, leading to substantial doubt about its ability to continue as a going concern. While cost-cutting measures and capital raises provide some liquidity, they do not address the fundamental issue of insufficient revenue generation from key product launches (inFoods IBS and hp+detect), which have been slower than expected. The reliance on further capital raises, potential dilution, and intense competition in a highly regulated market, coupled with international risks, present a high-risk investment profile. The current financial instability and the explicit going concern warning from the auditor suggest a 'sell' recommendation for investors seeking to mitigate risk.

Keywords

Biomerica, BMRA, Diagnostic Products, IBS, Irritable Bowel Syndrome, H. pylori, Helicobacter pylori, inFoods Technology, hp+detect, Medical Devices, Biomedical Technology, Clinical Laboratories, Point-of-Care Testing, FDA Clearance, CE Mark, SEC Filing, 10-K, Financial Results, Going Concern, Capital Raise, Intellectual Property, Medical Diagnostics, Gastrointestinal Health, Contract Manufacturing, Workforce Reduction